{"filing":{"accession_number":"0001193125-26-276691","cik":"0001770069","ticker":"MPLT","company_name":"MapLight Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-22","report_date":null,"primary_document":"d31456d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1770069/000119312526276691/d31456d8k.htm"},"events":[{"id":12568,"run_id":11147,"accession_number":"0001193125-26-276691","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"MapLight disclosed topline results from the Phase 2 IRIS trial of ML-004 in autism spectrum disorder on June 22, 2026. The trial did not meet its primary endpoint for social communication deficits but showed clinically meaningful improvement in irritability in adolescents with moderate-to-severe baseline irritability, with effect sizes comparable to approved antipsychotics.","company_name":"MapLight Therapeutics, Inc.","ticker":"MPLT","filing_date":"2026-06-22","form":"8-K","submitted_at":null,"items":[{"id":9454,"accession_number":"0001193125-26-276691","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"MapLight disclosed topline results from the Phase 2 IRIS trial of ML-004 in autism spectrum disorder, presented at a June 22, 2026 conference call. The trial did not meet its primary endpoint (social communication deficits) but showed clinically meaningful improvement in irritability in an adolescent subgroup with moderate-to-severe baseline irritability (ABC-I ≥ 16), with effect sizes comparable to approved antipsychotics. This is a material clinical development milestone for a biopharmaceutical company's lead candidate, affecting investor assessment of the program's viability and regulatory pathway, though it falls outside the specific named event types (not earnings, not M\u0026A, not a restatement or going-concern issue).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T11:10:11.023642+00:00","company_name":"","ticker":null,"filing_date":""},{"id":9455,"accession_number":"0001193125-26-276691","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"MapLight announced topline results from its Phase 2 IRIS trial evaluating ML-004 in autism spectrum disorder on June 22, 2026. While the primary endpoint (social communication deficits) was not met, the company disclosed clinically meaningful improvements in irritability in adolescents with moderate-to-severe baseline irritability, with effect sizes comparable to approved antipsychotics. This is a material clinical development milestone that would affect investor assessment of the company's pipeline and regulatory prospects, but it is not a traditional earnings release, M\u0026A activity, or other specifically-named event type—it is a clinical trial result announcement for a product candidate under development.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T11:10:11.023642+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9454,"accession_number":"0001193125-26-276691","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"MapLight disclosed topline results from the Phase 2 IRIS trial of ML-004 in autism spectrum disorder, presented at a June 22, 2026 conference call. The trial did not meet its primary endpoint (social communication deficits) but showed clinically meaningful improvement in irritability in an adolescent subgroup with moderate-to-severe baseline irritability (ABC-I ≥ 16), with effect sizes comparable to approved antipsychotics. This is a material clinical development milestone for a biopharmaceutical company's lead candidate, affecting investor assessment of the program's viability and regulatory pathway, though it falls outside the specific named event types (not earnings, not M\u0026A, not a restatement or going-concern issue).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T11:10:11.023642+00:00","company_name":"MapLight Therapeutics, Inc.","ticker":"MPLT","filing_date":"2026-06-22"},{"id":9455,"accession_number":"0001193125-26-276691","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"MapLight announced topline results from its Phase 2 IRIS trial evaluating ML-004 in autism spectrum disorder on June 22, 2026. While the primary endpoint (social communication deficits) was not met, the company disclosed clinically meaningful improvements in irritability in adolescents with moderate-to-severe baseline irritability, with effect sizes comparable to approved antipsychotics. This is a material clinical development milestone that would affect investor assessment of the company's pipeline and regulatory prospects, but it is not a traditional earnings release, M\u0026A activity, or other specifically-named event type—it is a clinical trial result announcement for a product candidate under development.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T11:10:11.023642+00:00","company_name":"MapLight Therapeutics, Inc.","ticker":"MPLT","filing_date":"2026-06-22"}]}